期刊文献+

伦理审查视角下非注册临床研究方案常见问题刍议——基于某三甲医院近十年伦理审查样本的分析 被引量:4

Preliminary Discussion on Common Problems of Non-Registered Clinical Research Programs from the Perspective of Ethical Review:An Analysis of Ethical Review Samples in a Third-Class A Hospital in the Past Ten Years
下载PDF
导出
摘要 对某三甲医院2008年至2017年伦理审查的非注册临床研究方案进行了分析,发现方案的常见问题主要集中在纳排标准不严谨、样本量的确定缺少依据、观察指标设置不合理、研究背景不充分,缺乏必要的立题依据、隐私和保密条款缺如等方面。原因在于研究人员伦理意识淡薄,临床研究方案设计能力不足,对方案制定的重视度不够。建议临床研究人员在方案制定上多下功夫,在夯实科研基础的同时正确处理好科研与伦理的关系。 This paper analyzed the non-registered clinical research program of ethical review in a third-class hospital from 2008 to 2017,and found that the common problems of the program mainly focused on the imprecise standards of inclusion and exclusion,the lack of basis for determining sample size,the unreasonable setting of observation indicators,the insufficient research background,the lack of necessary basis for topic setting,and the lack of privacy and confidentiality provisions.The reasons were as follows:the lack of ethical awareness of researchers,inadequate ability to design clinical research programs,and insufficient attention to program formulation.It is suggested that clinical researchers should pay more attention to the formulation of the program,and properly handle the relationship between scientific research and ethics while consolidating the foundation of scientific research.
作者 杨竟 陈秀琴 蒋璐灿 陈勇川 YANG Jing;CHEN Xiuqin;JIANG Lucan;CHEN Yongchuan(Ethics Committee,First Affiliated Hospital of Army Medical University,Chongqing 400038,China;Clinical Laboratory,Chongqing Traditional Chinese Medicine Hospital,Chongqing 400021,China)
出处 《中国医学伦理学》 2019年第3期345-349,共5页 Chinese Medical Ethics
基金 2016年陆军军医大学第一附属医院军事与战创伤救治临床新技术计划项目"医学研究伦理审查规范体系建设研究"(SWH2016BZGFGJJ-01)
关键词 伦理审查 非注册临床研究方案 样本分析 Ethical Review Non-Registered Clinical Research Programs Sample Analysis
  • 相关文献

参考文献5

二级参考文献25

  • 1ICH指导委员会.人群暴露程度:评价无生命威胁条件下长期治疗药物的临床安全性.药品注册的国际技术要求[M].北京:人民卫生出版社,2007:1-5.
  • 2ICH指导委员会.临床研究的一般考虑.药品注册的国际技术要求[M].北京:人民卫生出版社,2007:251-265.
  • 3FDA. Providing clinical evidence of effectiveness for human drug and bi- ological products [ EB/OL]. http://www. fda. ggv/cder/guidance/, 2007 - 11 - 12.
  • 4Eclat DS, Liebson PR, Mitchell LB ,et al . Mortality and mobidity in patients receiving encainide flecainide , or placebo. The cardiac arrlaythmia suppression trial [ J ]. N Engl J Med, 1991 ; 329 : 781 - 788.
  • 5Fleming TR. Surrogate endpoints and FDA' s accelerated approval process [ J]. Health Aff,2005 ;24:67 - 68.
  • 6彭斯.医学伦理学经典案例[M].聂精保,胡林英,译.4版.长沙:湖南科学技术出版社,2010:446.
  • 7Wolpe P R. Reasons Scientists Avoid Thinking about Ethics[J]. Cell, 2006,125(6) :1023-1025.
  • 8Wiles R. Research governance and changes to the procedures for local research ethics cornmittees[J]. Physioherapy,2001,88(11):642-644.
  • 9张迅,林玲,邹琴,苏旭,王海英,何贤.临床医学科研的伦理审查探讨[J].现代预防医学,2008,35(3):508-509. 被引量:11
  • 10邱仁宗,翟晓梅.在国际背景下我国伦理审查的能力建设:理念和实践[J].中国医学伦理学,2008,21(2):3-5. 被引量:35

共引文献59

同被引文献62

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部